Results 141 to 150 of about 50,966 (210)

A patient-specific multidisciplinary approach to improve patient outcomes in IgG4-related ophthalmic disease. [PDF]

Indian J Ophthalmol
Moreker MR.
europepmc   +1 more source

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. [PDF]

N Engl J Med
Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR, Australasian Leukaemia and Lymphoma Group.   +19 more
europepmc   +1 more source

A Novel NPHS1-Associated Phenotype Characterized by Recurrent Transient Proteinuria. [PDF]

Case Rep Nephrol
Tanaka E, Konomoto T, Sakaguchi H, Kurogi J, Sakakibara N, Nozu K, Moritake H.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cyclosporine

Southern Medical Journal, 1986
Cyclosporine is a fungal metabolite increasingly used as an immunosuppressive agent in organ transplantation. It provides immunosuppression primarily through reversible inhibition of T-lymphocytes, without myelotoxicity. Cyclosporine appears to inhibit primary activation of helper cells and to decrease the production of lymphokines by these cells ...
S E, Thomas, D S, Gordon
openaire   +2 more sources

Cyclosporine

Drug Intelligence & Clinical Pharmacy, 1985
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients ...
R J, Ptachcinski, G J, Burckart, R, Venkataramanan   +2 more
openaire   +2 more sources